As of 4:30 PM 11/13/14 All times are local (Market data is delayed by at least 15 minutes).
prana biotechnology ltd (PRNAF) Key Developments
Prana Biotechnology Limited - Shareholder/Analyst Call
Nov 11 14
Annual General Meeting
Prana Biotechnology Limited Announces Executive Changes
Nov 3 14
Prana Biotechnology Limited announced the appointment of Ms. Kathryn Andrews as Chief Financial Officer and Mr. Phillip Hains as Company Secretary. Ms Andrews is a Certified Practicing Accountant and has over 25 years' experience in accounting, commercial management and consulting in various roles. For the past two years Ms. Andrews has held a senor role with The CFO Solution. As principal of The CFO Solution since 1996, Mr. Hains is the Company Secretary for a number of listed companies in the life sciences sector. The appointment follows the resignation of Mr. Richard (Rick) Revelins from the role of CFO and Company Secretary to pursue other commercial interests in the USA. The changes are effective immediately.
Prana Biotechnology Limited announced delayed 20-F filing
Oct 31 14
On 10/31/2014, Prana Biotechnology Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Prana Biotechnology Limited, Annual General Meeting, Nov 13, 2014
Oct 14 14
Prana Biotechnology Limited, Annual General Meeting, Nov 13, 2014., at 11:30 AUS Eastern Standard Time. Location: Giorgios Restaurant Function Room. Agenda: To receive and consider the 2014 annual financial statements of the company in respect of the year ended 30 June 2014 and comprising the annual financial report, the directors’ report and the auditor’s report; to approve executive changes; to approve ratification of previously issued securities-ATM; and to consider any other business that may be brought before the meeting in accordance with the constitution of the company and the Corporations Act.
Prana Biotechnology Limited Receives US Food and Drug Administration Orphan Drug Designation for PBT2 for Huntington Disease
Sep 5 14
Prana Biotechnology Limited has announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. Orphan drug designation is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. Orphan drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the treatment of Huntington disease; protocol assistance by the FDA to optimize drug development in the preparation of a dossier that will meet regulatory requirements; and reduced fees associated with applying for market approval. The company will also be applying for Orphan Drug designation in Europe and other jurisdictions. Prana announced in February 2014 that its lead MPAC (Metal Protein Attenuating Compound) PBT2 had met its primary end point of safety and tolerability, and improved measures of cognitive performance - a secondary endpoint in its Reach2HD Phase 2 clinical trial involving 109 people with Huntington disease. Prana is preparing its Post Phase 2 Trial dossier for submission to the FDA to commence discussions on the next development steps for PBT2.
Sponsored Financial Commentaries